MGF (Mechano Growth Factor) vs IGF-1 DES
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Mechano Growth Factor, IGF-1Ec
MGF is the name given to a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that muscle switches on after loading or damage. The "MGF" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the E-domain, sequence YQPPSTNKNTKSQRRKGSTFEEHK), often with a modified C-terminus. It got famous through early lab work from Geoffrey Goldspink's group suggesting it kicks muscle stem cells into action. The honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials.
Also: des(1-3)IGF-1, Des(1-3) IGF-I
IGF-1 DES is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. That small cut makes it bind poorly to the IGF binding proteins that normally keep IGF-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. It occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. There are no human trials of it at all, so everything said about it in people is extrapolation.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | MGF (Mechano Growth Factor) | IGF-1 DES |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The idea goes like this. When muscle is stretched or injured, the IGF-1 gene is spliced differently, producing a version with a different C-terminal E-domain. Researchers proposed that this E-domain gets cut off and acts on its own, pushing satellite cells (muscle stem cells) to multiply before mature IGF-1 tells them to fuse and build new fibers. Several studies reported that the E-peptide works without the classic IGF-1 receptor, and in heart cells it was reported to enter the cell, travel to the nucleus, and block the mitochondrial apoptosis pathway. The problem is that nobody has identified MGF's receptor, a 2010 Endocrinology review pointed out that no matching peptide has ever been isolated from cells, tissue or blood, and a 2014 study from Novartis and another drug company could not reproduce the core muscle-cell effects. So the mechanism is a hypothesis built on synthetic-peptide experiments, not established biology. | Like regular IGF-1, des(1-3)IGF-1 activates the type 1 IGF receptor, a tyrosine kinase receptor closely related to the insulin receptor. That switches on PI3K/Akt and MAPK signalling, which drives cell growth, protein synthesis and glucose uptake. The difference is the binding proteins. In the body almost all IGF-1 rides around bound to IGFBPs, which limit how much can hit the receptor. Removing the N-terminal tripeptide (Gly-Pro-Glu) sharply weakens IGFBP binding while leaving receptor binding intact. In a 1992 JCI study on rat granulosa cells, des(1-3)IGF-1 was about 10 times more potent than intact IGF-1 when binding proteins were present, and roughly equal once they were removed, which shows the extra potency comes from dodging the binding proteins rather than a stronger receptor hit. The trade-off: unbound IGF-1 is cleared fast, so its action is short and local, which is why people inject it into a specific muscle. It also carries IGF-1's insulin-like effect on blood sugar. |
| Common Dosing | No established human dose Not established | Community-reported 20-100 mcg per day Usually once daily on training days |
| Administration | Local injection or infusion into tissue in animal studies; research-market products are injected | Intramuscular or subcutaneous injection (community practice); studied by injection in animals only |
| Typical Duration | Single treatments or days to weeks in animal models; no human protocols exist | Community reports describe short cycles of about 4-6 weeks; there is no human data on safe duration |
| Best Time to Take | Not established | Around training, per community practice |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The supportive work is real but almost all in cells and animals. Yang and Goldspink (FEBS Letters, 2002) reported that the E-domain increased myoblast proliferation and delayed differentiation. Kandalla and colleagues (2011) reported it extended the proliferative lifespan of human muscle precursor cells from young donors, but not from old donors. In sheep with induced heart attacks, local MGF E-domain preserved cardiac function and cut compromised heart muscle by about 35% (Carpenter, 2008), and similar heart-protection results came from mouse studies. A gerbil stroke model showed strong neuroprotection (Dluzniewska, 2005). Then the counterpoint: Fornaro and colleagues (Am J Physiol Endocrinol Metab, 2014) tested MGF up to 500 ng/ml on mouse and human muscle cells and primary muscle stem cells and saw no effect on proliferation or differentiation, while real IGF-1 worked fine. An accompanying editorial was titled "The Fall of Mechanogrowth Factor?". In humans, the only solid data is about gene expression: heavy leg extensions raised MGF mRNA in young men but not in older men (Hameed, 2003). There are no human dosing studies and no clinical trials. One more flag: MGF E-peptide drove growth of prostate cancer cells in a lab study, and MGF was found overexpressed in prostate cancer tissue (Armakolas, 2010). | The research is old, small, and entirely in cells and animals. Sara, Carlsson-Skwirut and colleagues isolated a truncated variant of IGF-1 from human fetal brain in 1986 (PNAS). In GH-deficient lit/lit mice, Gillespie and colleagues (J Endocrinol, 1990) found that 3 microgram daily injections of des(1-3)IGF-1 increased body length about as much as 30 micrograms of regular IGF-1, confirming its higher potency in a living animal; organ weights (kidney, heart) also rose. Adashi and colleagues (JCI, 1992) showed the roughly 10-fold potency gain disappears when IGF binding proteins are removed. Beyond that, it is mostly a lab tool for studying the IGF system. There are no human trials, no pharmacokinetic data in people, and no safety data. Claims about local muscle hyperplasia, fat loss, or recovery are bodybuilding lore built on IGF-1 biology, not on studies of this peptide. Theoretical risks are the same as for IGF-1 and other analogues: low blood sugar, and long-term concerns about feeding the growth of existing tumours, since IGF-1 signalling is a known growth pathway in several cancers. Quality is another unknown: the material sold online has no pharmaceutical oversight. |
Frequently Asked Questions: MGF (Mechano Growth Factor) vs IGF-1 DES
What is the difference between MGF (Mechano Growth Factor) and IGF-1 DES?
MGF (Mechano Growth Factor) is a growth hormone peptide that mgf is the name given to a splice variant of the igf-1 gene (igf-1ec in humans, igf-1eb in rodents) that muscle switches on after loading or damage. the "mgf" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the e-domain, sequence yqppstnkntksqrrkgstfeehk), often with a modified c-terminus. it got famous through early lab work from geoffrey goldspink's group suggesting it kicks muscle stem cells into action. the honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials. IGF-1 DES is a growth hormone peptide that igf-1 des is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. that small cut makes it bind poorly to the igf binding proteins that normally keep igf-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. it occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. there are no human trials of it at all, so everything said about it in people is extrapolation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, MGF (Mechano Growth Factor) or IGF-1 DES?
Neither is universally "better" - the choice depends on your specific goals. MGF (Mechano Growth Factor) is typically used for growth hormone purposes, while IGF-1 DES is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can MGF (Mechano Growth Factor) and IGF-1 DES be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using MGF (Mechano Growth Factor) and IGF-1 DES together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.